Assessment of the Biodistribution and Safety of [18F]MNI-968 (Aka PF-06730110) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs 18F-MNI-968 (Primary)
- Indications Neurodegenerative disorders
- Focus Diagnostic use
- 05 Mar 2018 Status changed from recruiting to completed.
- 06 Oct 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 06 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.